Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:16:30 EDT Wed 08 Oct 2025
Enter Symbol
or Name
USA
CA



Q:BCLI - BRAINSTROM CELL THERAPEUTICS - https://www.brainstorm-cell.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BCLI - Qnot subscribed0.73+0.034.324.316490.70  0.75  0.702.68  0.52115:57:40Aug 1415 min RT 2¢

Recent Trades - Last 10 of 49
Time ETExPriceChangeVolume
15:57:40Q0.7455210.04552180
15:36:35Q0.739350.0393510
15:35:50Q0.730.03100
15:24:59Q0.730.035
15:22:28Q0.731870.031876
15:13:04Q0.74860.0486500
15:05:21Q0.735610.035615
14:39:51Q0.7346750.03467525
14:24:32Q0.74410.044146
14:08:01Q0.7440250.044025100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-08-14 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
2025-08-08 07:00U:BCLINews ReleaseBrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
2025-07-17 16:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
2025-07-08 07:00U:BCLINews ReleaseFDA Review of Citizen Petition Offers a Fresh Look at NurOwn(TM)'s Evidence of Treatment Effectiveness
2025-06-16 08:30U:BCLINews ReleaseBrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn(TM)
2025-05-27 07:00U:BCLINews ReleaseBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn(TM) Phase 3b ALS Clinical Trials
2025-05-19 07:00U:BCLINews ReleaseBrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(TM) for ALS
2025-05-15 16:05U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
2025-05-15 07:30U:BCLINews ReleaseBrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19
2025-05-07 06:30U:BCLINews ReleaseBrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025
2025-05-06 07:00U:BCLINews ReleaseBrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit
2025-04-29 06:30U:BCLINews ReleaseBrainStorm's NurOwn(TM) Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting
2025-04-10 07:30U:BCLINews ReleaseBrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn(TM) in ALS
2025-03-31 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
2025-03-26 08:15U:BCLINews ReleaseBrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
2025-03-24 07:00U:BCLINews ReleaseBrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update
2024-12-30 08:00U:BCLINews ReleaseBrainStorm Issues 2024 Letter to Shareholders
2024-12-09 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Host Investor Call and Provide a Corporate Update
2024-12-03 07:00U:BCLINews ReleaseBrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology
2024-12-02 07:00U:BCLINews ReleaseBrainStorm Cell Therapeutics to Host KOL Webinar on Current Developments in the Treatment of Amyotrophic Lateral Sclerosis (ALS) on December 11, 2024